



GLENN HEGAR TEXAS COMPTROLLER OF PUBLIC ACCOUNTS

MEMORANDUM

October 6, 2022

TO: Texas Opioid Abatement Fund Council

FROM: Amanda Lopez, Director

RE: **FY 2022 Revenue from Settlement Agreements/Court Orders**

There are no new revenues from the settlement agreements or court orders to report at this time. The accounts did grow on account of earnings received, but remain similar to the overall totals for the different accounts shared at the August 9th meeting.

<i>AY</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
2022	McKinsey	4,540,343.02	Opioid Abatement Account/ State share; Unappropriated
2022	McKinsey	197,362.26	Opioid Abatement Account/ State share; Unappropriated
2022	J&J/Jansen	39,492,329.75	Opioid Abatement Account/ State share; Unappropriated
2022	Endo	8,373,408.75	Opioid Abatement Account/ State share; Unappropriated
2022	Teva	4,730,437.50	Opioid Abatement Account/ State share; Unappropriated
Total		57,333,881.28	

2022	Endo	38,575,907.50	Trust fund share
2022	Teva	22,075,375.00	Trust fund share
2022	Interest	108,831.01	Trust fund share interest
Total		60,760,113.51	

2022	Endo	7,873,408.75	Subdivision share
2022	Teva	4,730,437.50	Subdivision share
2022	Interest	7,069.86	Subdivision share interest
Total		12,610,916.11	